HUSSEIN TAWBI to Biphenyl Compounds
This is a "connection" page, showing publications HUSSEIN TAWBI has written about Biphenyl Compounds.
Connection Strength
0.462
-
A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res. 2014 Apr 01; 20(7):1900-9.
Score: 0.433
-
A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. Clin Cancer Res. 2015 Feb 01; 21(3):585-93.
Score: 0.029